Access read Guideline inclusion is not a clinical formality in the United States, it is where coverage gets decided. Commercial plans write NCCN into oncology medical policy, practices build treatment pathways off it, and the compendia route carries coverage for uses that run past the label. Celcuity’s own release names payers among the guideline’s audience, which tells you what the announcement is for. What makes it worth logging is the order. The listing lands sixteen days after approval and roughly two months before there is a product to sell, so the reimbursement case is being built during the supply delay rather than after it. That inverts the usual launch failure, where the vials arrive and the payer policies do not. Two gates remain, and a guideline solves neither. The label turns on a negative biomarker, so patients qualify by what their tumour does not have, which means uptake tracks PIK3CA testing rates rather than coverage, and an untested patient is not eligible on paper. And Category 1 gets you onto the policy, not past utilisation management. At 72% stomatitis on the triplet with 22% Grade 3, discontinuation is the variable payers will model, because cost per completed course is what they actually price. Celcuity has not disclosed a price. Watch that number and the prior authorisation criteria that follow it, because the guideline was the easy part.